Autonomix Medical Files 8-K with Corporate Updates
Ticker: AMIX · Form: 8-K · Filed: Mar 4, 2024 · CIK: 1617867
Sentiment: neutral
Topics: corporate-filing, regulation-fd
TL;DR
Autonomix Medical filed an 8-K on Feb 29, 2024, updating corporate info and filings.
AI Summary
Autonomix Medical, Inc. filed an 8-K on February 29, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's principal executive offices located at 21 Waterway Avenue, Suite 300, The Woodlands, TX 77380, and provides its telephone number as (713) 588-6150. The company is incorporated in Delaware and operates in the Surgical & Medical Instruments & Apparatus industry.
Why It Matters
This filing provides essential corporate information and disclosures for Autonomix Medical, Inc., which is important for investors and stakeholders to stay informed about the company's operational and financial reporting status.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks or material adverse information.
Key Players & Entities
- Autonomix Medical, Inc. (company) — Registrant
- February 29, 2024 (date) — Date of earliest event reported
- 21 Waterway Avenue, Suite 300, The Woodlands, TX 77380 (location) — Principal executive offices
- (713) 588-6150 (phone_number) — Registrant's telephone number
- Delaware (jurisdiction) — State of incorporation
- 3841 (sic_code) — Standard Industrial Classification
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits as of February 29, 2024.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on February 29, 2024.
Where are Autonomix Medical, Inc.'s principal executive offices located?
Autonomix Medical, Inc.'s principal executive offices are located at 21 Waterway Avenue, Suite 300, The Woodlands, TX 77380.
What is the telephone number for Autonomix Medical, Inc.?
The telephone number for Autonomix Medical, Inc. is (713) 588-6150.
In which state is Autonomix Medical, Inc. incorporated?
Autonomix Medical, Inc. is incorporated in Delaware.
Filing Stats: 796 words · 3 min read · ~3 pages · Grade level 12.1 · Accepted 2024-03-04 09:05:13
Key Financial Figures
- $0.001 — ch Registered Common Stock, par value $0.001 per share AMIX The Nasdaq Stock Marke
Filing Documents
- autonomix_8k.htm (8-K) — 29KB
- autonomix_ex9901.htm (EX-99.1) — 26KB
- image_001.jpg (GRAPHIC) — 3KB
- image_049.jpg (GRAPHIC) — 24KB
- image_050.jpg (GRAPHIC) — 78KB
- image_051.jpg (GRAPHIC) — 34KB
- image_052.jpg (GRAPHIC) — 35KB
- image_053.jpg (GRAPHIC) — 36KB
- image_054.jpg (GRAPHIC) — 24KB
- image_055.jpg (GRAPHIC) — 35KB
- image_056.jpg (GRAPHIC) — 42KB
- image_057.jpg (GRAPHIC) — 39KB
- image_058.jpg (GRAPHIC) — 42KB
- image_059.jpg (GRAPHIC) — 29KB
- image_060.jpg (GRAPHIC) — 42KB
- image_061.jpg (GRAPHIC) — 22KB
- image_062.jpg (GRAPHIC) — 49KB
- image_063.jpg (GRAPHIC) — 42KB
- image_064.jpg (GRAPHIC) — 40KB
- image_065.jpg (GRAPHIC) — 24KB
- image_066.jpg (GRAPHIC) — 34KB
- image_067.jpg (GRAPHIC) — 32KB
- image_068.jpg (GRAPHIC) — 32KB
- image_069.jpg (GRAPHIC) — 45KB
- image_070.jpg (GRAPHIC) — 28KB
- image_071.jpg (GRAPHIC) — 17KB
- 0001683168-24-001265.txt ( ) — 1384KB
- amix-20240229.xsd (EX-101.SCH) — 3KB
- amix-20240229_lab.xml (EX-101.LAB) — 33KB
- amix-20240229_pre.xml (EX-101.PRE) — 22KB
- autonomix_8k_htm.xml (XML) — 4KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure As previously announced in a press release by Autonomix Medical, Inc. (the "Company") on February 23, 2024, the Company's Chief Executive Officer, Lori Bisson, participated in a "Virtual Investor What This Means Segment" on February 29, 2024. A live video webcast of the event will be available on the Events page under the Investors section of the Company's website (autonomix.com). A webcast replay will be accessible for 90 days. A copy of the conference presentation is attached to this report as Exhibit 99.1 and is incorporated by reference herein. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be "filed" for the purpose of the Securities Exchange Act of 1934, as amended ("Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference. Some of the statements in the conference presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Forward-looking statements are identified by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predicti
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits Exhibit No. Exhibit 99.1 "Virtual Investor What This Means Segment" Conference Presentation dated February 29, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AUTONOMIX MEDICAL, INC. By: /s/ Trent Smith Trent Smith Chief Financial Officer Dated: March 4, 2024 3